157 related articles for article (PubMed ID: 38369264)
41. Establishment of a prognostic signature for lung adenocarcinoma using cuproptosis-related lncRNAs.
Yalimaimaiti S; Liang X; Zhao H; Dou H; Liu W; Yang Y; Ning L
BMC Bioinformatics; 2023 Mar; 24(1):81. PubMed ID: 36879187
[TBL] [Abstract][Full Text] [Related]
42. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
Front Immunol; 2021; 12():693062. PubMed ID: 34497605
[TBL] [Abstract][Full Text] [Related]
43. A novel senescence-related lncRNA signature that predicts prognosis and the tumor microenvironment in patients with lung adenocarcinoma.
Fang X; Huang E; Xie X; Yang K; Wang S; Huang X; Song M
Front Genet; 2022; 13():951311. PubMed ID: 36406130
[No Abstract] [Full Text] [Related]
44. Identification of a pyroptosis-related lncRNA signature in the regulation of prognosis, metabolism signals and immune infiltration in lung adenocarcinoma.
Zhou S; Cai Y; Xu Z; Peng B; Liang Q; Peng J; Yan Y
Front Endocrinol (Lausanne); 2022; 13():964362. PubMed ID: 36034461
[TBL] [Abstract][Full Text] [Related]
45. Identification and Validation of a Novel Six-lncRNA-Based Prognostic Model for Lung Adenocarcinoma.
Yang L; Wu Y; Xu H; Zhang J; Zheng X; Zhang L; Wang Y; Chen W; Wang K
Front Oncol; 2021; 11():775583. PubMed ID: 35111670
[TBL] [Abstract][Full Text] [Related]
46. A prognostic and immunotherapy effectiveness model for pancreatic adenocarcinoma based on cuproptosis-related lncRNAs signature.
Zhang N; Yu X; Sun H; Zhao Y; Wu J; Liu G
Medicine (Baltimore); 2023 Oct; 102(42):e35167. PubMed ID: 37861553
[TBL] [Abstract][Full Text] [Related]
47. Big data analysis identified a telomere-related signature predicting the prognosis and drug sensitivity in lung adenocarcinoma.
Zhang W
Medicine (Baltimore); 2023 Nov; 102(46):e35526. PubMed ID: 37986388
[TBL] [Abstract][Full Text] [Related]
48. Molecular map of disulfidptosis-related genes in lung adenocarcinoma: the perspective toward immune microenvironment and prognosis.
Zhao F; Su L; Wang X; Luan J; Zhang X; Li Y; Li S; Hu L
Clin Epigenetics; 2024 Feb; 16(1):26. PubMed ID: 38342890
[TBL] [Abstract][Full Text] [Related]
49. Identification of an antigen-presenting cells/T/NK cells-related gene signature to predict prognosis and CTSL to predict immunotherapeutic response for lung adenocarcinoma: an integrated analysis of bulk and single-cell RNA sequencing.
Huang L; Lou N; Xie T; Tang L; Han X; Shi Y
Cancer Immunol Immunother; 2023 Oct; 72(10):3259-3277. PubMed ID: 37458771
[TBL] [Abstract][Full Text] [Related]
50. Prognostic signature of lipid metabolism associated LncRNAs predict prognosis and treatment of lung adenocarcinoma.
Zhao J; Li G; Zhao G; Wang W; Shen Z; Yang Y; Huang Y; Ye L
Front Oncol; 2022; 12():986367. PubMed ID: 36387240
[TBL] [Abstract][Full Text] [Related]
51. Identification of a three-gene expression signature and construction of a prognostic nomogram predicting overall survival in lung adenocarcinoma based on TCGA and GEO databases.
Zhou Y; Gao S; Yang R; Du C; Wang Y; Wu Y
Transl Lung Cancer Res; 2022 Jul; 11(7):1479-1496. PubMed ID: 35958325
[TBL] [Abstract][Full Text] [Related]
52. Identification of a disulfidptosis-related genes signature for prognostic implication in lung adenocarcinoma.
Huang J; Zhang J; Zhang F; Lu S; Guo S; Shi R; Zhai Y; Gao Y; Tao X; Jin Z; You L; Wu J
Comput Biol Med; 2023 Oct; 165():107402. PubMed ID: 37657358
[TBL] [Abstract][Full Text] [Related]
53. Development of six immune-related lncRNA signature prognostic model for smoking-positive lung adenocarcinoma.
Zhou D; Wang J; Liu X
J Clin Lab Anal; 2022 Jun; 36(6):e24467. PubMed ID: 35561270
[TBL] [Abstract][Full Text] [Related]
54. Development and validation of a prognostic risk signature for lung adenocarcinoma constructed by six ferroptosis, necroptosis, and pyroptosis-related lncRNAs.
Peng L; Ji J; Zhang C; Wu Z; Sun Y; Fan K; Du W; Liu A; Jiao W
J Thorac Dis; 2022 Oct; 14(10):3955-3974. PubMed ID: 36389299
[TBL] [Abstract][Full Text] [Related]
55. Comprehensive analysis of a novel signature incorporating lipid metabolism and immune-related genes for assessing prognosis and immune landscape in lung adenocarcinoma.
Wang Y; Xu J; Fang Y; Gu J; Zhao F; Tang Y; Xu R; Zhang B; Wu J; Fang Z; Li Y
Front Immunol; 2022; 13():950001. PubMed ID: 36091041
[TBL] [Abstract][Full Text] [Related]
56. Comprehensive analysis of m6A modification patterns and m6A-related lncRNAs as potential biomarkers in lung adenocarcinoma.
Wang S; Gu X; Xu D; Liu B; Qin K; Yuan X
Environ Toxicol; 2024 Apr; 39(4):2285-2303. PubMed ID: 38148718
[TBL] [Abstract][Full Text] [Related]
57. Disulfidptosis characterizes the tumor microenvironment and predicts immunotherapy sensitivity and prognosis in bladder cancer.
Pan G; Xie H; Xia Y
Heliyon; 2024 Feb; 10(3):e25573. PubMed ID: 38356551
[TBL] [Abstract][Full Text] [Related]
58. Prognostic Value of Genomic Instability of m
Li R; Li JP; Liu TT; Huo C; Yao J; Ji XL; Qu YQ
Front Cell Dev Biol; 2022; 10():707405. PubMed ID: 35309906
[No Abstract] [Full Text] [Related]
59. Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma.
Fu Y; Wei X; Han Q; Le J; Ma Y; Lin X; Xu Y; Liu N; Wang X; Kong X; Gu J; Tong Y; Wu H
BMC Cancer; 2021 Oct; 21(1):1165. PubMed ID: 34717566
[TBL] [Abstract][Full Text] [Related]
60. Relationships of N6-Methyladenosine-Related Long Non-Coding RNAs With Tumor Immune Microenvironment and Clinical Prognosis in Lung Adenocarcinoma.
Zhao J; Lin X; Zhuang J; He F
Front Genet; 2021; 12():714697. PubMed ID: 34777460
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]